round button
Chat now

全球多价抗蛇毒市场 – 行业趋势及 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球多价抗蛇毒市场 – 行业趋势及 2029 年预测

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Polyvalent Anti Venom Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 436.05 Million
Diagram Market Size (Forecast Year)
USD 629.67 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

全球多价抗蛇毒市场,按种类(蛇、蜘蛛、蝎子等)、作用方式(细胞毒性、神经毒性、血液毒性等)、最终用户(医院、专科诊所、门诊手术中心等)、分销渠道(医院药房、零售药房、网上药房等)划分 – 行业趋势和预测(至 2029 年)

多价抗蛇毒血清市场

市场分析和规模

近年来,预计多价抗蛇毒血清市场将在预测期内快速增长。在许多热带和亚热带国家,蛇咬是最容易被忽视的公共卫生问题之一。根据世界卫生组织 (WHO) 的数据,每年实际发生近 540 万起蛇咬事件,导致 270 万人中毒(蛇咬中毒)和约 81,000 至 131,000 人死亡。此外,它常常导致三倍的截肢和其他不可逆转的损伤。这导致多价抗蛇毒血清进入市场。

Data Bridge Market Research 分析称,2021 年多价抗蛇毒市场价值为 4.3605 亿美元,预计到 2029 年将达到 6.2967 亿美元,在 2022 年至 2029 年的预测期内复合年增长率为 4.70%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

纯化的抗体称为抗蛇毒血清,用于防止蛇毒附着在组织上并引起严重的过敏反应、血液凝结、肌肉损伤或神经系统问题。它们可以通过预防或逆转蛇咬中毒的后果来帮助降低死亡率和发病率。它们是利用各种技术从各种动物身上采集的,包括蛇、漏斗网蜘蛛、石鱼、红背蜘蛛和箱形水母。单价和多价抗蛇毒血清是两种不同的抗蛇毒血清。多价抗蛇毒血清是通过分离已用各种毒蛇种类的各种毒液免疫的动物血浆制成的。

报告范围和市场细分

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

种类(蛇、蜘蛛、蝎子等)、作用方式(细胞毒性、神经毒性、血液毒性等)、最终用户(医院、专科诊所、家庭护理等)、分销渠道(医院药房、零售药房、网上药房等)

覆盖国家

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Medtronic (Ireland), Boston Scientific Corporation (US), Medline Industries, Inc. (US), Thermo Fisher Scientific Inc. (US), Stryker (US), Johnson & Johnson Private Limited (US), Novo Nordisk A/S (Denmark), B. Braun Melsungen AG (Germany), BD (US), Terumo Medical Corporation (Japan), Smith+Nephew (UK), Merck KGaA (Germany),  Boehringer Ingelheim International GmbH. (Germany), Pfizer Inc. (US), GlaxoSmithKline plc (UK), CSL Limited (Australia), Rare Disease Therapeutics Inc. (US), Incepta Pharmaceuticals Ltd. (Bangladesh), HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD. (India), Bharat Serums and Vaccines Limited (India),Vins Bio products Limited(India), Merck & Co., Inc. (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Surge in drug approvals and new product launches

Polyvalent Anti-Venom Market Dynamics

Drivers

  • Rise in the incidence of animal bite

The rising incidence of animal bite such as snake and scorpion bites is anticipated to enhance the antifungal drugs market's growth rate. In the foreseeable future, a high prevalence of poisonous animal bites is anticipated to be a primary factor driving demand for anti-venom.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of polyvalent anti-venom market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about snake bites and its treatment will expand the polyvalent anti-venom market. Additionally, high disposable income and increasing level of investment for drug development will enhance the market's growth rate. Snake venom detection kits with a quick enzyme immunoassay for in vitro detection and immunological identification of snake venom in bite site samples, urine, plasma, blood, or other tissues and body fluids have been introduced. This is expected to provide lucrative growth prospects for industry players while also propelling the overall market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the polyvalent anti-venom market growth. Along with this, surge in drug approvals and new product launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the polyvalent anti-venom market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with polyvalent anti-venoms and treatment procedure with anti-venoms will obstruct the growth rate of market. The dearth of regulatory capacity for the control of anti-venoms and lack of healthcare infrastructure in developing economies will challenge the polyvalent anti-venom market. Additionally, side effects of polyvalent anti-venom will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This polyvalent anti-venom market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polyvalent anti-venom market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Polyvalent anti-venom market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Polyvalent Anti-Venom Market

在预测期内,多价抗蛇毒血清市场预计将受到 COVID-19 疫情的限制。自 2019 年 12 月出现以来,COVID-19  病毒已传播到地球上几乎每个国家,促使世界卫生组织 (WHO) 宣布其为公共卫生紧急事件。COVID-19 是一种新型冠状病毒,被确定为肺炎病例的病原体。这种病毒迅速传播到世界各地,造成大量人员死亡。世界卫生组织 (WHO) 于 2020 年 3 月将 COVID-19 列为全球大流行病,并建议采取严格措施防止该疾病的传播。自那以后,这场大流行推迟了医疗保健部门的扩张并扰乱了供应链。此外,许多国家的政府已实施全国封锁,以阻止 COVID-19 的蔓延。同样,世界各国的医疗保健组织也难以继续其供应链活动。供应链缓慢也阻碍了多价抗蛇毒血清市场的发展。

近期发展

  • 据 Rare Disease Therapeutics, Inc. 称,2021 年 4 月,美国食品药品监督管理局 (FDA) 批准了马源抗蛇毒血清 ANAVIP 的新扩大适应症,用于治疗北美蝰蛇中毒的成人和儿童患者。

全球多价抗蛇毒市场范围

多价抗蛇毒市场根据物种、作用方式、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

物种

  • 蜘蛛
  • 其他的

作用方式

  • 细胞毒
  • 神经毒性
  • 血液毒性
  • 其他的

最终用户

分销渠道

  • 医院药房
  • 零售药店
  • 网上药店
  • 其他的

多价抗蛇毒 市场区域分析/见解

对多价抗蛇毒市场进行了分析,并按国家、物种、作用方式、最终用户和分销渠道提供了市场规模洞察和趋势,如上所述。

多价抗蛇毒市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在多价抗蛇毒血清市场占据主导地位,因为该地区的研发活动数量不断增加。此外,主要关键参与者的不断增加和完善的医疗保健基础设施将进一步推动该地区市场的增长率。

由于医疗保健支出的增加和政府为改善医疗保健基础设施而采取的举措不断增多,预计亚太地区在预测期内将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和多价抗蛇毒 市场份额分析

多价抗蛇毒市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对多价抗蛇毒市场的关注有关。

多价抗蛇毒血清市场的一些主要参与者包括:

  • 美敦力(爱尔兰)
  • 波士顿科学公司 (美国)
  • Medline Industries, Inc.(美国)
  • 赛默飞世尔科技公司(美国)
  • 史赛克(美国)
  • 强生私人有限公司(美国)
  • 诺和诺德公司(丹麦)
  • B.Braun Melsungen AG(德国)
  • BD(美国)
  • Terumo Medical Corporation(日本)
  • Smith+Nephew(英国)
  • 默克集团(德国)
  • 勃林格殷格翰国际有限公司(德国)
  • 辉瑞公司(美国)
  • 葛兰素史克公司 (英国)
  • CSL有限公司(澳大利亚)
  • 罕见疾病治疗公司(美国)
  • Incepta Pharmaceuticals Ltd.(孟加拉国)
  • HAFFKINE 生物制药有限公司(印度)
  • 印度巴拉特血清和疫苗有限公司 (印度)
  • Vins Bio products Limited(印度)
  • 默克公司(美国) 

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Polyvalent Anti-Venom Market size will be worth USD 629.67 million by 2029.
The Polyvalent Anti-Venom Market growth rate is 4.70% by 2029.
Rise in the incidence of animal bite and Increasing investment for healthcare infrastructure are the growth drivers of the Polyvalent Anti-Venom Market.
The species, mode of action, end-users and distribution channel are the factors on which the Polyvalent Anti-Venom Market research is based.
The major companies in the Polyvalent Anti-Venom Market are Medtronic (Ireland), Boston Scientific Corporation (US), Medline Industries, Inc. (US), Thermo Fisher Scientific Inc. (US), Stryker (US), Johnson & Johnson Private Limited (US), Novo Nordisk A/S (Denmark), B. Braun Melsungen AG (Germany), BD (US), Terumo Medical Corporation (Japan), Smith+Nephew (UK), Merck KGaA (Germany), Boehringer Ingelheim International GmbH. (Germany), Pfizer Inc. (US), GlaxoSmithKline plc (UK), CSL Limited (Australia), Rare Disease Therapeutics Inc. (US), Incepta Pharmaceuticals Ltd. (Bangladesh), HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD. (India), Bharat Serums and Vaccines Limited (India),Vins Bio products Limited(India), Merck & Co., Inc. (US).
a